$340 Million is the total value of Ally Bridge Group (NY) LLC's 31 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RGEN | Sell | REPLIGEN CORP | $20,229,000 | +22.8% | 70,000 | -15.2% | 5.95% | +45.4% |
| ARVN | Sell | ARVINAS INC | $17,258,000 | -6.6% | 210,000 | -12.5% | 5.07% | +10.5% |
| NUVB | Sell | NUVATION BIO INC | $16,510,000 | +3.8% | 1,660,947 | -2.8% | 4.85% | +22.9% |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $8,720,000 | -42.2% | 65,000 | -30.2% | 2.56% | -31.6% |
| NVTA | Sell | INVITAE CORP | $5,683,000 | -43.8% | 199,900 | -33.4% | 1.67% | -33.5% |
| CYT | Sell | CYTEIR THERAPEUTICS INC | $5,608,000 | -58.2% | 319,538 | -49.0% | 1.65% | -50.5% |
| BOLT | Sell | BOLT BIOTHERAPEUTICS INC | $3,254,000 | -48.9% | 257,267 | -37.6% | 0.96% | -39.6% |
| FRLN | Exit | FREELINE THERAPEUTICS HLDGSsponsored ads | $0 | – | -401,747 | -100.0% | -0.81% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -128,572 | -100.0% | -0.99% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -1.34% | – |
| AVIR | Exit | ATEA PHARMACEUTICALS INC | $0 | – | -373,288 | -100.0% | -1.99% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -363,185 | -100.0% | -2.58% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -675,670 | -100.0% | -4.30% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.